$2.2M
+$442K this year3 filings since 2025 · latest Equity filed
NurExone Biologic Inc. is a publicly traded biopharmaceutical company based in Canada, specializing in the development of innovative treatments for neurological injuries, particularly focusing on spinal cord injuries. Their research and products aim to address the significant need for effective recovery solutions for patients suffering from acute spinal cord trauma.
What sets it apart
NurExone's unique focus on non-invasive exosome-based therapies, like ExoPTEN, sets it apart from traditional treatment methodologies.
ExoPTEN is an exosome-loaded nanodrug designed to facilitate neuron regeneration and restore motor, sensory, and functional abilities in patients who have recently experienced acute spinal cord injuries.
